Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
New York, New York–(Newsfile Corp. – January 4, 2025) – A leading financial law firm Bleichmar Fonti & Auld LLP publishes a study at BioAge Labs, Inc. (NASDAQ: BIOA) for possible violations of federal securities laws.
If you have invested in BioAge, you are encouraged to find out more by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Why is BioAge Researched?
BioAge Labs, Inc. is a leading biopharmaceutical company engaged in the development of therapeutic products for metabolic diseases, with a particular focus on obesity. The company’s flagship product, azelaprag, is an orally available small molecule apelin receptor (APJ) inhibitor, designed to improve weight loss.
At the time, the company said that azelaprag was well tolerated in 265 people across eight Phase 1 trials and that after the company’s IPO it was “well equipped to advance our clinical programs.” (.).”
The Stock Fails When The Truth Is Revealed
On December 6, 2024, BioAge announced that it had stopped its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in people receiving azelaprag. The company said the decision to stop the STRIDES Phase 2 study of azelaprag “was made clear” due to “the emerging safety profile of the tested doses (.)”
The news caused the company’s stock price to drop more than 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
What would you do?
If you have invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is subject to a contingency fee, at no cost to you. Shareholders are not responsible for court costs or litigation expenses. The firm will seek court approval for possible fees and costs.
Enter your details by visiting:
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities and shareholder litigation. Named among the top 5 plaintiffs’ law firms by ISS SCAS in 2023 and its attorneys named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its most recent notable achievements, BFA received a valuation of over $900 million from Tesla (NASDAQ: ), Inc.’s Board of Directors. (pending court approval), as well as $420 million from Teva Pharmaceutical (NYSE: ) Ind. Ltd.
To learn more about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases-investigations/bioage-labs-inc
Advertising attorney. Past results do not guarantee future results.
To view the source version of this release, please visit https://www.newsfilecorp.com/release/235856
